Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial

•Treatment with DAC HYP 150 mg significantly improved HRQoL in patients with RRMS.•This benefit is likely due to reducing the risk of relapse and disability progression.•MS-specific HRQoL measures better capture the treatment effect on HRQoL.

BackgroundThe SELECT study demonstrated superior effects of daclizumab high-yield process (DAC HYP) to placebo in key endpoints in patients with relapsing and remitting multiple sclerosis (RRMS).ObjectiveTo assess the impact of DAC HYP and disease activity on health-related quality of life (HRQoL) using data from this study.MethodsHRQoL was assessed at baseline, 12, 24, and 52 weeks using the Multiple Sclerosis Impact Scale (MSIS-29), the 12-items Short Form Health Survey, and the EuroQoL-5 Dimensions. An analysis of covariance model was used to compare treatment difference in change from baseline. Mixed-effects models were used to assess the impact of disability progression, relapse, treatment, and interaction between treatment and these events on HRQoL outcome.ResultsDAC HYP 150 mg resulted in significant positive impacts on HRQoL compared to placebo. It was also found to significantly reduce the adverse impact of relapse on the MSIS-29 physical scale (−12.45; p=0.0006). Relapse and disability progression were significantly associated with impaired HRQoL.ConclusionDAC HYP 150 mg improved HRQoL in patients with RRMS compared to placebo. The treatment benefit can be partially attributed to reduction in disease activity and attenuation of the adverse impact of relapse on HRQoL.